Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 study of montelukast for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia

Next Previous
X
Search
Trial Profile

Phase 2 study of montelukast for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Montelukast (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Adverse reactions; Proof of concept

    • Most Recent Events

    • 22 Aug 2016 According to an IntelGenx media release, the company expects results from this study to be available in Q4 of 2017.
    • 22 Aug 2016 According to an IntelGenx media release, patient enrolment for this study is expected to commence in Q1 of 2017.
    • 18 Jul 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top